diclofenac has been researched along with cp-55,940 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Astles, PC; Chambers, MG; Hollinshead, SP; Johnson, MP; Palmer, J; Tidwell, MW | 1 |
| Astles, PC; Chambers, MG; Guidetti, R; Hollinshead, SP; Johnson, MP; Oskins, J; Palmer, J; Sanderson, A; Stratford, R; Tidwell, MW | 1 |
| Chai, X; Chen, S; Jiang, BE; Jiang, X; Liang, Q; Liu, M; Lu, W; Qiu, ZL; Sun, XB; Yang, JJ; Yi, C; Yu, LF; Zhang, HK; Zhang, Q | 1 |
3 other study(ies) available for diclofenac and cp-55,940
| Article | Year |
|---|---|
Discovery and optimization of novel purines as potent and selective CB2 agonists.
Topics: Animals; Drug Evaluation, Preclinical; Furans; Half-Life; Humans; Pain; Purines; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2012 |
Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
Topics: Animals; Dogs; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Male; Osteoarthritis; Purines; Rats; Rats, Inbred Lew; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2013 |
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
Topics: Designer Drugs; Drug Discovery; Humans; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Structure-Activity Relationship | 2021 |